2023 World Conference on Lung Cancer (Posters)-EP11.03. Efficacy and Safety of Chemotherapy Plus Immunotherapy and Recombinant Human Endostatin in Advanced Non-small-Cell Lung Cancer

EP11.03. Efficacy and Safety of Chemotherapy Plus Immunotherapy and Recombinant Human Endostatin in Advanced Non-small-Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the efficacy and safety of chemotherapy plus immunotherapy and recombinant human endostatin in patients with advanced non-small cell lung cancer (NSCLC). The study included 24 patients diagnosed with advanced NSCLC who were treated with this combination therapy at Guangzhou Chest Hospital. The main outcomes evaluated were progression-free survival (PFS) and objective response rate (ORR), while the secondary outcomes were disease control rate (DCR) and adverse events (AEs).<br /><br />The results showed that at a median follow-up of 20 months, the median PFS was 11 months. Among the patients who received first-line treatment, the median PFS was also 11 months. The 6-month and 12-month PFS rates were 82.4% and 52.9%, respectively. The first-line treatment achieved an ORR of 58.8% and a DCR of 94.1%. Grade 3-4 treatment-related adverse events occurred in 11.8% of patients, with hematotoxicity being the most common. Grade 1-2 treatment-mediated adverse events were observed in 47.1% of patients, with hematotoxicity, pruritus, and hepatic toxicity being the most common.<br /><br />Overall, chemotherapy plus immunotherapy and recombinant human endostatin showed promising efficacy and a manageable safety profile in patients with advanced NSCLC. <br /><br />In conclusion, this study demonstrates that this combination therapy could be a viable option for the treatment of advanced NSCLC.

Asset Subtitle

Shan Su

Meta Tag

Speaker Shan Su

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

chemotherapy

immunotherapy

endostatin

NSCLC

efficacy

safety

PFS

ORR

DCR

adverse events